Holen Sie sich die Stockscreener-App
4.65
6.41%
0.28
Handel nachbörslich:
4.67
0.02
+0.43%
Schlusskurs vom Vortag:
$4.37
Offen:
$4.47
24-Stunden-Volumen:
4.24M
Relative Volume:
1.57
Marktkapitalisierung:
$1.34B
Einnahmen:
$9.77M
Nettoeinkommen (Verlust:
$-109.00M
KGV:
-12.90
EPS:
-0.3604
Netto-Cashflow:
$-93.83M
1W Leistung:
+14.25%
1M Leistung:
+1.75%
6M Leistung:
+5.20%
1J Leistung:
+281.15%
1-Tages-Spanne:
$4.47
$4.735
1-Wochen-Bereich:
$4.16
$4.735
52-Wochen-Spanne:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.65 | 1.26B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00 - MarketBeat
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Taysha Gene Therapies price target on trial progress - investing.com
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
5 Best Multibagger Penny Stocks to Invest In - Insider Monkey
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation - MSN
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Aug Patterns: Is Taysha Gene Therapies Inc undervalued by DCF analysis2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Should you avoid Taysha Gene Therapies Inc stock right nowProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Buybacks Report: Is Taysha Gene Therapies Inc undervalued by DCF analysisQuarterly Investment Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Catalysts: Will Taysha Gene Therapies Inc benefit from AI trendsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial - MarketBeat
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha Gene Therapies FY 2025 earnings preview - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
BMO Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Q4 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
4.52 |
1,655 |
7,481 |
1,442,131 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):